Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XYF19 CAR-T in R/R CD19+ Malignancies
NCT04037566Phase 1Unknown
- Sponsor
- Xijing Hospital
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XYF19 CAR-T cell therapy in acute lymphoblastic leukemia (ALL) and B cell lymphoma, sponsored by Xijing Hospital. Primary endpoints: Adverse events associated with XYF19 CAR-T cells product at 30 days and Maximum Tolerated Dose at 30 days. Status: unknown.
02
Drugs
XYF19 CAR-T cell therapy
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT04037566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037566.